Technical Reports on Drug Makers Equities -- TherapeuticsMD, GlaxoSmithKline, Novartis, and Impax Labs

Thursday, July 20, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 20, 2017 /PRNewswire/ --

If you want a Stock Review on TXMD, GSK, NVS, or IPXL then come over to

and sign up for your free customized report today. Today's research on is centered on the following major players in the Drug Manufacturers space: TherapeuticsMD Inc. (NYSE MKT: TXMD), GlaxoSmithKline PLC (NYSE: GSK), Novartis AG
(NYSE: NVS), and Impax Laboratories Inc. (NASDAQ: IPXL). These companies operate in the Pharmaceutical industry, which discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications. Learn more about these stocks by downloading their comprehensive and free reports from member's area at:


On Wednesday, shares in Boca Raton, Florida headquartered TherapeuticsMD Inc. climbed 1.71%, ending the day at $5.35. The stock recorded a trading volume of 3.21 million shares, which was above its three months average volume of 2.90 million shares. The Company's shares have advanced 0.19% in the last one month and 6.79% over the previous three months. The stock is trading above its 50-day moving average by 12.93%. Moreover, shares of TherapeuticsMD, which operates as a women's health care product company, have a Relative Strength Index (RSI) of 54.45.

On July 11th, 2017, research firm Oppenheimer upgraded the Company's stock rating from 'Perform' to 'Outperform'.

On July 17th, 2017, TherapeuticsMD announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR - the Company's treatment for dyspareunia. The Company was able to present new information that could address concerns raised by the US Food and Drug Administration (FDA) and positively affect the status of the NDA. The Company continues to have a productive dialogue with the FDA, and expects to have additional clarity on the pathway forward for the NDA for TX-004HR in the coming weeks. TXMD complete research report is just a click away at:


Shares in Brentford, the UK headquartered GlaxoSmithKline PLC ended the day 0.02% lower at $42.42 with a total trading volume of 1.77 million shares. In the previous three months and on an YTD basis, the stock has gained 3.87% and 10.15%, respectively. The Company's shares are trading above their 200-day moving average by 3.44%. Furthermore, shares of GlaxoSmithKline, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI of 41.56.

On July 05th, 2017, research firm Citigroup downgraded the Company's stock rating from 'Buy' to 'Neutral'. The complimentary report on GSK can be downloaded at:


At the close of trading on Wednesday, shares in Basel, Switzerland headquartered Novartis AG finished 0.31% higher at $85.03 with a total trading volume of 1.74 million shares. The stock has advanced 4.41% in the last one month, 16.90% over the previous three months, and 16.74% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 3.83% and 12.28%, respectively. Additionally, shares of Novartis, which researches, develops, manufactures, and markets healthcare products worldwide, have an RSI of 63.19.

On July 05th, 2017, research firm Credit Suisse downgraded the Company's stock rating from 'Neutral' to 'Underperform'. Sign up for your complimentary research report on NVS at:

Impax Laboratories 

Hayward, California headquartered Impax Laboratories Inc.'s shares recorded a trading volume of 2.06 million shares at the end of yesterday's session, which was above their three months average volume of 1.78 million shares. The stock closed the day 3.29% lower at $17.65. The Company's shares have surged 21.31% in the past month, 40.64% in the previous three months, and 33.21% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.37% and 18.97%, respectively. Additionally, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have an RSI of 60.89.

On June 29th, 2017, Impax Labs announced that it will release its Q2 2017 financial results on August 09th, 2017, prior to the open of the US financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. ET that same day. The financial results and live webcast will be accessible under the Investor Relations section of the Company's website.

On July 18th, 2017, research firm Piper Jaffray upgraded the Company's stock rating from 'Underweight' to 'Neutral'. Get free access to your research report on IPXL at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store